{"id":"W2918036803","doi":"10.21037/sci.2019.02.01","title":"Personalized chemotherapy in triple-negative breast cancer: are we ready for prime time?","year":2019,"lang":"en","type":"letter","venue":"Stem Cell Investigation","topic":"Breast Cancer Treatment Studies","field":"Biochemistry, Genetics and Molecular Biology","cited_by":1,"is_retracted":false,"has_abstract":true,"ca_institutions":"","funders":"EMD Serono; Genentech; Sierra Oncology; Ipsen; Astex Pharmaceuticals; Exelixis; Daiichi-Sankyo; Pfizer; Eisai; Merck KGaA; Array BioPharma; AstraZeneca; Eli Lilly and Company","keywords":"Triple-negative breast cancer; Breast cancer; Medicine; Oncology; Estrogen receptor; Internal medicine; Progesterone receptor; Chemotherapy; Cancer; Estrogen; Epidermal growth factor receptor","routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0001182801,0.0004800718,0.0005400581,0.0001020851,0.00007671612,0.00003178981,0.000211484,0.0007277756,0.00004331138],"category_scores_gemma":[0.000007936503,0.0004593312,0.0001676577,0.0001299425,0.0001769278,0.000008844076,0.00004686506,0.0003149535,0.00003396252],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0002731489,"about_ca_system_score_gemma":0.0002916368,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0002625132,"about_ca_topic_score_gemma":0.00006711703,"domain_scores_codex":[0.9981097,0.0001376898,0.0003426526,0.0007948443,0.0002230466,0.0003920583],"domain_scores_gemma":[0.9988063,0.0000713888,0.0005074011,0.0003963585,0.0001748381,0.00004373131],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","study_design_scores_codex":[0.0003849361,0.00004190936,0.003122417,0.0005095453,0.0002947125,0.000005104744,0.0006101244,0.00001380043,0.01855994,0.000002870539,0.9751453,0.001309339],"study_design_scores_gemma":[0.01234312,0.0003390786,0.006467565,0.001050391,0.000346466,0.00002395697,0.0003443751,0.000178217,0.1801539,0.0003341281,0.7967275,0.001691294],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","genre_codex":"commentary","genre_gemma":"commentary","genre_scores_codex":[0.04544521,0.007667921,0.0001229672,0.9312567,0.00129723,0.006106097,0.006789713,0.0001011543,0.001213046],"genre_scores_gemma":[0.03451009,0.007790624,0.002216227,0.7377512,0.01594009,0.006964853,0.02461871,0.0009552725,0.1692529],"genre_candidate":"commentary","genre_consensus":"commentary","teacher_disagreement_score":0.1935054,"threshold_uncertainty_score":0.9997858,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02515456554210938,"score_gpt":0.2617261301684112,"score_spread":0.2365715646263018,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}